Here's why the Rhythm (ASX:RHY) share price is soaring 8% today

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22. Here's what the company announced to the ASX.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22.

During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%.

Rhythm moves ahead with strategic plans

Investors appear to be pleased with the company's progress to commercialise its cancer detection technology, ColoSTAT, driving Rhythm shares higher.

In its announcement, Rhythm highlighted a number of activities that it is moving forward to launch ColoSTAT into global markets.

The first of its listed strategic initiatives is to accelerate United States market entry for ColoSTAT. The company has incorporated a wholly-owned entity to cement its foothold in the country to carry operations out smoothly. The initial pathway stages to obtain market approval from the United States Food and Drug Administration (FDA) has already commenced.

In addition, Rhythm has expanded its platform by setting up an Australian entity to hold its technology within. The company validated initial data that its lead biomarker has a global market opportunity for cancer diagnostics.

Regulatory entry in both Europe (CE Mark) and Australia is advancing ahead of completion in its ColoSTAT Study 7. CE Mark filing is slated for late 2021, and the Australian Therapeutic Goods Administration (TGA) has begun the regulatory approval process.

Lastly, the company is looking at further market entry strategies in Europe, Australia, New Zealand, China, and broader Asia. Further updates in regards to this are expected to be released to the ASX in the coming months.

Notably, the company is targeting its first revenue for late 2022.

Comments from the CEO

Rhythm CEO, Mr. Glenn Gilbert commented:

Following the exceptional ColoSTAT performance results from Study 6 and the LRF algorithm enhancement work, this has given the company confidence to now accelerate the execution of our commercial strategy, focusing on our path to market activities.

ColoSTAT will transform the global mass-market cancer diagnostic market, with exciting and positive impacts at a social and economic level.

About the Rhythm share price

The Rhythm share price has been one of the best performers over the last 12 months, rising more than 1,000%. The company's shares were trading at 6.3 cents in June before accelerating later that year.

It's worth noting that the Rhythm share price is trading just below its all-time high of $1.675, reached in March.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares are slipping again. Is the comeback already over?

The healthcare stock needs evidence of recovering demand before rallying further.

Read more »

A young couple sits at their kitchen table looking at documents with a laptop open in front of them.
Healthcare Shares

ResMed's $490m MatrixCare sale: What it means

ResMed announces $490 million sale of MatrixCare and future shareholder returns.

Read more »

Married elderly man and woman in love spending time together on bench on a phone, symbolising retirement.
Healthcare Shares

Summerset Group delivers Q2 update

Summerset Group saw first-half FY26 sales rise 17%, with resales up 26%.

Read more »

A guy shrugs his shoulders, not sure which is the right decision.
Healthcare Shares

Cochlear shares are flying. Is this just the start?

Up 32% in a month, but can the ASX healthcare stock reach $300 again?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

2 ASX 200 healthcare shares to buy after sector rebounds 23% in a month

The rapid rebound in ASX 200 healthcare shares has caught many investors by surprise.

Read more »

A medical researcher in a white coat holds laboratory equipment and smiles.
Healthcare Shares

2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?

With a 13% to 34% recovery over the past month, do experts believe it's sustainable?

Read more »

Man sleeping with a sleep apnoea mask on.
Broker Notes

Down 22%! 3 reasons to buy the big dip in ResMed shares today

Two leading analysts deliver their verdicts on ResMed’s beaten-down share price.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

ASX healthcare shares have jumped 21% since June. Can the recovery continue?

Can ASX healthcare shares can sustain their recovery?

Read more »